Puma Biotechnology Inc at H C Wainwright BioConnect Conference (Virtual) Transcript
Hello, and welcome, everyone, to the H.C. Wainwright 2021 BioConnect Conference. My name is Stephen Bersey. I'm an equity research associate here at H.C. Wainwright. I'd like to introduce our next presenter, Alan Auerbach, who is CEO of Puma Biotechnology. They're focused on the acquisition and development of novel therapeutics for the treatment of cancer. So Alan?
Thank you very much, Stephen, and welcome, everyone, to the Puma Biotechnology presentation. Just a reminder, I'll be making forward-looking statements.
So on this slide, you can see all of the work that we're doing with our drug, neratinib, across the breast cancer and other cancer therapy space. The drug is currently on the market in HER2-positive breast cancer, both for the extended adjuvant indication as well as the metastatic, which is based on the Phase III results of our ExteNET trial and our NALA trial. We also have an ongoing Phase II, combining the drug with T-DM1, which is the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
